IMV  logo

Annual report 2022
added 12-21-2024

report update icon

IMV Market Cap 2011-2025 | IMV

As of December 04, 2025 IMV has a market cap of $ 13.1 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap IMV

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 90.5 M 153 M 144 M 226 M 201 M 56.7 M 43.2 M 45.1 M 47.5 M 20.4 M 17.8 M
202220222021202120202020201920192018201820172017201620162015201520142014201320132012201220112011240 M240 M180 M180 M120 M120 M60 M60 M00
Download SVG
Download PNG
Download CSV

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
226 M 17.8 M 95 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
AC Immune SA AC Immune SA
ACIU
305 M $ 2.8 2.19 % $ 229 M schweizSchweiz
ADiTx Therapeutics ADiTx Therapeutics
ADTX
59.2 K $ 2.49 -11.39 % $ 32.8 K usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
149 M $ 4.59 -4.08 % $ 98.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
484 M - 1052.0 % $ 415 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
Akouos Akouos
AKUS
172 M - 0.23 % $ 488 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
1.83 B $ 12.12 -1.58 % $ 3.74 B usaUSA
Axcella Health Axcella Health
AXLA
25 M - -16.42 % $ 249 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
12.1 M - 2.71 % $ 14 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
133 M $ 5.37 -20.68 % $ 194 M usaUSA
Atreca Atreca
BCEL
49 M - -11.76 % $ 5.79 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
6.33 M - -2.5 % $ 5.88 M usaUSA
argenx SE argenx SE
ARGX
13.8 B $ 919.62 2.76 % $ 25 B niderlandNiderland
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
7.37 B $ 203.0 -3.72 % $ 5 B danmarkDanmark
Achieve Life Sciences Achieve Life Sciences
ACHV
90.2 M $ 4.64 -0.32 % $ 92 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
308 M - -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
253 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
895 M $ 3.36 2.73 % $ 8.08 B australiaAustralia
Acasti Pharma Acasti Pharma
ACST
40.7 M - 4.01 % $ 150 M canadaCanada
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
78.6 M - -74.18 % $ 955 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
1.35 B $ 3.29 -1.5 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
13.1 B $ 54.27 -1.38 % $ 10.3 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
2.05 B - -15.15 % $ 60.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Baudax Bio Baudax Bio
BXRX
779 K - 0.59 % $ 63 K usaUSA
AbbVie AbbVie
ABBV
342 B $ 224.99 -0.01 % $ 398 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
54.1 M - -3.03 % $ 260 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
3.43 B - - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
1.82 M - - $ 3.74 B usaUSA
BioNTech SE BioNTech SE
BNTX
62.9 B $ 96.22 -1.21 % $ 27.2 B germanyGermany
Codiak BioSciences Codiak BioSciences
CDAK
240 M - -55.98 % $ 2.15 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
1.18 B $ 18.75 -0.48 % $ 2.76 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
423 M - - $ 789 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
5.37 M $ 1.92 -7.01 % $ 4.87 M usaUSA
Biogen Biogen
BIIB
19.3 B $ 179.76 1.11 % $ 26.2 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
6.68 B - - $ 7.29 B usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
1.08 M - -5.16 % $ 5.39 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
2.5 B $ 23.52 -2.22 % $ 1.94 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
859 M $ 3.45 -0.72 % $ 1.02 B canadaCanada
Cabaletta Bio Cabaletta Bio
CABA
20.5 M $ 2.37 -2.67 % $ 2.77 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
101 M - - $ 25.3 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
21.1 M - -6.63 % $ 13.9 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
231 M - -7.23 % $ 13 M usaUSA
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
52.7 M - - $ 231 M usaUSA
Chimerix Chimerix
CMRX
104 M - - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
103 M - - $ 401 M usaUSA